CNS Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 14.04 million compared to USD 9.46 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.57 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2172 USD | +6.47% | +7.52% | -82.90% |
Apr. 23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call | |
Apr. 01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-82.90% | 2.17M | |
+1.92% | 42.59B | |
+8.36% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.75% | 24.81B | |
-24.19% | 18.17B | |
+28.83% | 12.05B | |
-3.06% | 11.7B | |
+6.96% | 11.1B |
- Stock Market
- Equities
- CNSP Stock
- News CNS Pharmaceuticals, Inc.
- CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021